Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Vir Biotechnology has a “Moderate Buy” consensus rating from eight analysts, with six buys, one strong buy and one sell. The average 12-month price target is $21.57 versus a recent share price of $11.39.
• Institutional investors own 65.32% of VIR, with several firms recently initiating or increasing positions in the company.
• Vir reported quarterly EPS of $0.47, beating the $0.33 consensus estimate, while revenue of $238.95 million significantly exceeded expectations and rose sharply year over year.

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has received an average rating of "Moderate Buy" from the eight research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $21.5714.

VIR has been the topic of several analyst reports. Wall Street Zen raised shares of Vir Biotechnology from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vir Biotechnology in a report on Wednesday, July 8th. HC Wainwright reissued a "buy" rating on shares of Vir Biotechnology in a research note on Monday, August 10th. Leerink Partners boosted their price target on shares of Vir Biotechnology from $20.00 to $21.00 and gave the stock an "outperform" rating in a research note on Wednesday, June 3rd. Finally, Morgan Stanley set a $25.00 target price on Vir Biotechnology in a report on Thursday, August 6th.

Institutional Trading of Vir Biotechnology

A number of institutional investors have recently modified their holdings of VIR. Fiduciary Financial Advisors acquired a new stake in Vir Biotechnology during the second quarter worth approximately $29,000. Raymond James Financial Inc. acquired a new position in Vir Biotechnology in the 2nd quarter valued at $35,000. UMB Bank n.a. lifted its position in shares of Vir Biotechnology by 1,418.7% during the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company's stock valued at $43,000 after acquiring an additional 6,597 shares during the period. CWM LLC lifted its position in shares of Vir Biotechnology by 23.0% during the 4th quarter. CWM LLC now owns 8,804 shares of the company's stock valued at $53,000 after acquiring an additional 1,646 shares during the period. Finally, Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Vir Biotechnology during the 4th quarter valued at $60,000. 65.32% of the stock is currently owned by institutional investors.

Vir Biotechnology Stock Down 0.5%

VIR stock opened at $11.39 on Friday. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -6.12 and a beta of 1.63. Vir Biotechnology has a 12 month low of $4.75 and a 12 month high of $11.94. The firm has a 50 day moving average of $9.74 and a two-hundred day moving average of $9.44.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.14. Vir Biotechnology had a negative return on equity of 29.99% and a negative net margin of 638.88%.The company had revenue of $238.95 million during the quarter, compared to the consensus estimate of $135.88 million. During the same quarter in the prior year, the company posted ($0.80) EPS. The firm's revenue was up 19582.5% on a year-over-year basis. On average, research analysts expect that Vir Biotechnology will post -1.84 EPS for the current fiscal year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source